Ebuzer Kalender

Dr. Ebuzer Kalender

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2011 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
EKEbuzer Kalender
Ebuzer Kalender
MYMustafa Yilmaz
Mustafa Yilmaz
SESuna Erkilic
Suna Erkilic
MYMehmet Yilmaz
Mehmet Yilmaz
ZCZeki Celen
Zeki Celen
Primary cutaneous diffuse large B-cell lymphoma is an uncommon type of non-Hodgkin lymphomas. A 51-year-old man had 2 gradually enlarging reddish, firm, and painless cutaneous-subcutaneous masses surrounded with some erythematous patches on his back for 3 years. Skin biopsy result was consistent with diffuse large B-cell lymphoma. FDG PET/CT was performed for staging and demonstrated bilaterally increased FDG uptake in the cutaneous masses with hypermetabolic left axillary lymph nodes. After chemotherapy, FDG PET/CT demonstrated that all FDG-avid lesions resolved, and there is a complete response to therapy.

24 February 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
EKEbuzer Kalender
Ebuzer Kalender
EEEdanur Ekinci
Edanur Ekinci
UEUmut Elboga
Umut Elboga
EŞErtan Şahin
Ertan Şahin
Objectives: Metastatic castration-resistant prostate cancer (mCRPC) is associated with poor prognosis, particularly in cases of liver metastases. 177Lu-PSMA-617 (commercially known as Pluvicto) is an FDA-approved radioligand therapy for mCRPC patients. This study aimed to evaluate the efficacy of 177Lu-PSMA-617 radioligand therapy (RLT) in mCRPC patients with liver metastases, focusing on progression-free survival (PFS), overall survival (OS), and factors influencing treatment response. Materials and Methods: This retrospective study included mCRPC patients (n = 32) with liver metastases treated with Lu-PSMA-617. Patient data, including prostate-specific antigen (PSA) levels, liver SUVmax values, Lutetium-PSMA therapy cycles, and survival outcomes, were collected. Kaplan–Meier survival analysis was used to calculate PFS and OS, while regression analysis was employed to identify factors associated with treatment response. Results: The median PFS and OS were 6 and 9 months, respectively. Partial regression was observed in patients with significantly lower PSA levels (median: 90.0 ng/mL, range: 22–699 ng/mL, p = 0.001) and liver SUVmax values (median: 17.9, range: 8.3–57.0, p = 0.008). A higher number of Lutetium-PSMA cycles correlated with improved treatment response (p = 0.010) and reduced liver SUVmax values (p = 0.043). Conclusions: Lu-PSMA-617 therapy is effective in managing mCRPC with liver metastases. Increased intensity of therapy exposure, reflected by a higher number of treatment cycles, is associated with a greater biochemical response, as indicated by reduced PSA levels, thereby supporting the rationale for personalized treatment strategies. These findings support the use of Lu-PSMA-617 in mCRPC patients with liver metastases, warranting further prospective studies.

4 December 2025 in Clinical and Translational Imaging
Verified
Journal Article
Closed access
PDF file
EKEbuzer Kalender
Ebuzer Kalender
EYEdanur Ekinci Yıldırım
Edanur Ekinci Yıldırım
VÇVuslat Mumcu Çimen
Vuslat Mumcu Çimen
BEBuket Eren
Buket Eren
UEUmut Elboğa
Umut Elboğa
EYEnes Yerdeş
Enes Yerdeş

30 November 2023 in Experimental and Applied Medical Science
Verified
Journal Article
Open access
PDF file
EKEbuzer Kalender
Ebuzer Kalender
VÇVuslat Çi̇men
Vuslat Çi̇men
UEUmut Elboga
Umut Elboga
UÇUfuk Çi̇men
Ufuk Çi̇men
ZÇZeki Çelen
Zeki Çelen
The purpose of this study is to evaluate the impact of 68Ga-DOTATE PET/CT on the management of medullary thyroid carcinoma (MTC). Eighteen patients (9 males and 9 females) with MTC who underwent 68Ga-DOTATE PET/CT for elevated calcitonin(Ct) levels were included in this study. Histopathological data, laboratory findings, 68Ga-DOTATE PET/CT findings were evaluated for each patient. 68Ga-DOTATATE PET/CT imaging findings were negative in 5 of 18 patients (27.8%) and positive in 13 of 18 patients (72.2%). The mean Ct level of patients with positive findings was higher than others. 68Ga-DOTATATE PET/CT was insufficient for detecting liver metastases in two patients who exhibited hypermetabolic uptakes consistent with solitary metastases in the liver on 18FDG-PET/CT. We believe that 68Ga-DOTATATE PET/CT plays an important role in the management of MTC patients with recurrent or metastatic disease. Its sensitivity is directly proportional to the levels of serum Ct. However, it may have limitations in detecting liver metastases.

10 October 2025 in Research Square
Verified
Preprint
Open access
PDF file
EKEbuzer Kalender
Ebuzer Kalender
EEEdanur Eki̇nci̇
Edanur Eki̇nci̇
VÇVuslat Mumcu Çi̇men
Vuslat Mumcu Çi̇men
BEBuket Eren
Buket Eren
UEUmut Elboğa
Umut Elboğa
EŞErtan Şahi̇n
Ertan Şahi̇n
Objective: Breast cancer (BC) ranks among the most frequently diagnosed malignancies worldwide. Therefore, a reliable and accurate staging tool is essential. PET/CT is a diagnostic radioisotropic modality used in the diagnosis of BC. The objective of this study was to compare the diagnostic value of 68Ga-FAPI-04 PET/CT and 18F-FDG PET/CT in assessing primary breast tumors and axillary lymph node metastases. Methods; This retrospective study included forty-two female patients with histopathologically confirmed axillary lymph node metastases. All participants underwent both FDG and FAPI PET/CT imaging within the same week. SUVMax values of primary and metastatic lesions were recorded, and the results were subjected to statistical analysis. Results; When the primary lesion 18 F-FDG SUVMax (8.1±5.8) was compared with 68Ga-FAPI SUVMax (15.43±6.4), 68Ga-FAPI SUVMax was higher (p<0.0001). 18F-FDG detected lymph node metastases in 26 patients. 18F-FDG did not detect lymph node metastasis in 16 patients. 68Ga-FAPI detected lymph node metastases in 39 patients. 68Ga-FAPI failed to detect lymph node metastases in 3 patients. 68Ga-FAPI was more effective than 18F-FDG in detecting axillary lymph node metastasis (p=0.02 x2=5.125). The SUVMax values of the detected lymph nodes were higher with 68Ga-FAPI (10.3±5.8) than with 18F-FDG (7.0±4.3) (p=0.015). The sensitivity of 68Ga-FAPI (92.86%) was higher than that of 18F-FDG (61.9%). According to histopathologic subtypes; invasive ductal carcinoma (IDC), 68Ga-FAPI was higher than 18F-FDG SUVMax (p<0.0001). Histopathologic subtypes of invasive lobular carcinoma (ILC) and invasive mucinous carcinoma (IMC) did not differ. According to molecular subtypes, the luminal A, luminal B and Her2+ 68Ga-FAPI SUVMax values were higher than the 18F-FDG SUVMax values (p=0.01, p<0.0001 and p=0.01, respectively). There was no difference in triple negative molecular subtypes. Conclusions: 68Ga-FAPI-04 PET/CT is superior to 18F-FDG PET/CT in the detection of axillary lymph node metastasis of breast cancer with high sensitivity and high SUVMax value.

9 July 2026 in Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
EYEnes Yerdes
Enes Yerdes
EKEbuzer Kalender
Ebuzer Kalender